14 completed, 2 terminated. 9 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 7 | Completed 5, Terminated 2 |
Follow ispinesib: new trials by email Literature Review of ispinesib trials Research Report on ispinesib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ispinesib in Metastatic Breast Cancer Ispinesib - Breast Neoplasms | Phase 1 | Terminated | Cytokinetics | 16 | 2007-12-01 | 2019-05-06 |
| Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-01-16 |
| Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer ispinesib - Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2006-05-01 | 2013-06-05 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel ispinesib, pharmacological study, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2005-04-01 | 2013-01-25 |
| SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer ispinesib - Liver Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 15 | 2005-03-08 | 2023-08-04 |
| SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer ispinesib, laboratory biomarker analysis, pharmacological study - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2005-01-01 | 2017-03-06 |
| SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer ispinesib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2005-01-01 | 2015-03-02 |
| Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer Ispinesib - Ovarian Cancer | Phase 2 | Completed | GlaxoSmithKline | 35 | 2004-12-01 | 2010-10-04 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes ispinesib, laboratory biomarker analysis, pharmacological study - Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-12-01 | 2013-01-11 |
| SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma ispinesib - Melanoma (Skin) | Phase 2 | Completed | NCIC Clinical Trials Group | 17 | 2004-11-01 | 2013-05-17 |
| Ispinesib In Combination With Capecitabine In Patients With Solid Tumors Ispinesib, Capecitabine - Solid Tumor Cancer | Phase 1 | Completed | GlaxoSmithKline | 30 | 2004-11-01 | 2008-10-16 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Terminated | National Cancer Institute (NCI) | 31 | 2004-11-01 | 2013-01-14 |
| Ispinesib In Combination With Carboplatin In Patients With Solid Tumors SB-715992, carboplatin - Solid Tumours | Phase 1 | Completed | GlaxoSmithKline | 30 | 2004-10-20 | 2017-09-25 |
| Study Of Ispinesib In Subjects With Breast Cancer Ispinesib - Neoplasms, Breast | Phase 2 | Completed | GlaxoSmithKline | 50 | 2004-06-30 | 2018-02-26 |
| SB-715992 In Combination With Docetaxel In Patients With Solid Tumors docetaxel, SB-715992 - Solid Tumor Cancer | Phase 1 | Completed | GlaxoSmithKline | 30 | 2004-06-01 | 2008-10-16 |
| Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer Ispinesib - Non-Small-Cell Lung Cancer | Phase 2 | Completed | GlaxoSmithKline | 70 | 2003-12-01 | 2010-10-04 |
Breast Neoplasms (2) · Burkitt Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Astrocytoma (1) · Blast Crisis (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Choroid Plexus Neoplasms (1) · Colonic Neoplasms (1) · Congenital Abnormalities (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Familial ependymoma (1) · Hodgkin Disease (1)
National Cancer Institute (NCI) (7) · GlaxoSmithKline (6) · NCIC Clinical Trials Group (2) · Cytokinetics (1)
United States (11) · United Kingdom (4) · Canada (3) · Belgium (2) · Malaysia (1) · Peru (1) · Singapore (1)
Andrew A Wolff, MD, FACC (1) · Brenda Cooper (1) · Christopher Lee, MD (1) · Eric Winquist (1) · Jennifer Knox, MD (1) · Patricia LoRusso (1) · Richard Sills (1) · Sharlene Gill, MD (1) · Syma Iqbal, MD (1) · Tomasz Beer (1) · Walter Stadler (1)
N01CM62201 (1), N01CM62203 (1), U01CA062487 (1), U01CA062502 (1), U01CA062505 (1), U01CA097452 (1), U10CA032102 (1)